A class action lawsuit has been filed against Medpace Holdings, Inc. on behalf of shareholders for alleged securities fraud. The lawsuit was triggered after Medpace reported a book-to-bill ratio of 1.04 on February 9, 2026, significantly below company guidance, causing the stock to plunge 15.9% to $446.05 per share. The class period covers April 22, 2025 through February 9, 2026.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Medpace Holdings, with a June 8, 2026 deadline for lead plaintiff claims. The lawsuit alleges Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Additional class actions are mentioned for Veritone, Inc. and Babcock & Wilcox Enterprises, Inc.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Rosen Law Firm is urging investors who purchased Veritone, Inc. securities between October 14, 2025 and April 14, 2026 to join a class action lawsuit before the July 20, 2026 lead plaintiff deadline. The lawsuit alleges that Veritone made false statements about its financial performance, inaccurately recorded revenue and costs, overstated assets, and maintained deficient internal controls, leading to required financial statement restatements.

Rosen Law Firm is notifying investors in Medpace Holdings, Upstart Holdings, and Babcock & Wilcox Enterprises of securities class action lawsuits. The firm alleges that Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Investors with losses exceeding $100,000 are encouraged to secure counsel before the June 8, 2026 deadline to potentially serve as lead plaintiffs.

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its business performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations, causing the stock to fall 15.9% on February 10, 2026. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Rosen Law Firm announces a securities class action lawsuit against Medpace Holdings, Inc. for allegedly making false statements about backlog cancellation rates and providing misleading growth projections. Investors who purchased MEDP stock between April 22, 2025 and February 9, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is June 8, 2026.

A securities class action lawsuit has been filed against Medpace Holdings, Inc. alleging that defendants made false and misleading statements regarding the company's backlog cancellation rates. The lawsuit claims defendants misrepresented cancellation rates as 'well behaved' and provided overly positive growth expectations that could not be sustained. Investors with losses exceeding $100,000 are encouraged to join the class action before the June 8, 2026 lead plaintiff deadline.

Rosen Law Firm has filed class action lawsuits against Veritone, Inc., Medpace Holdings, Inc., and Stellantis N.V. on behalf of investors who suffered losses. Veritone is accused of inaccurately recording revenue and costs, overstating financial metrics, and maintaining deficient internal controls, leading to required financial restatements. Investors who purchased securities during specified class periods may be eligible for compensation.

Rosen Law Firm is soliciting investors who suffered losses in Medpace Holdings, Stellantis N.V., and Blaize Holdings to join securities class action lawsuits. The Medpace case alleges the company made false statements about backlog cancellation rates and provided misleading growth projections. The lead plaintiff deadline for Medpace is June 8, 2026.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the company's book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.